Olmesartan-associated enteropathy: new insights on the natural history? Report of two cases

Scand J Gastroenterol. 2016;51(2):152-6. doi: 10.3109/00365521.2015.1074719. Epub 2015 Aug 20.


Introduction: The association between olmesartan and an enteropathy histologically indistinguishable from untreated celiac disease has recently been described. However, pathogenetic mechanisms leading to villous atrophy, prevalence, natural history and genetic background of this condition have not yet been defined.

Patients: We describe here two cases of olmesartan-associated enteropathy and discuss some aspects of the natural history of this condition.

Results: In both patients, an infectious episode seems to have triggered the severe malabsorption syndrome which led them to hospitalization. High titer positive antinuclear antibodies with homogeneous pattern were found.

Conclusions: Our reports add to a growing body of evidence suggesting that olmesartan-associated enteropathy should be considered in the presence of villous atrophy and negative celiac serology and in the diagnostic algorithm of non-responsive celiac disease.

Keywords: celiac disease; enteropathy; olmesartan; villous atrophy.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antihypertensive Agents / adverse effects*
  • Atrophy / chemically induced
  • Duodenal Diseases / chemically induced*
  • Duodenal Diseases / pathology*
  • Humans
  • Imidazoles / adverse effects*
  • Intestinal Mucosa / drug effects
  • Intestinal Mucosa / pathology*
  • Male
  • Middle Aged
  • Tetrazoles / adverse effects*


  • Antihypertensive Agents
  • Imidazoles
  • Tetrazoles
  • olmesartan